Fernando
Lecanda Cordero
Profesional Investigador
Centro Nacional de Investigaciones Oncológicas
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Centro Nacional de Investigaciones Oncológicas (8)
2023
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2020
-
Wnt signaling and Loxl2 promote aggressive osteosarcoma
Cell Research, Vol. 30, Núm. 10, pp. 885-901
2019
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2015
-
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types
Journal of the National Cancer Institute, Vol. 107, Núm. 12
2014
-
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633
2013
-
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Nature Genetics, Vol. 45, Núm. 7, pp. 799-803
2007
2004
-
Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis
Laboratory Investigation, Vol. 84, Núm. 8, pp. 999-1012